MLSS Quote, Financials, Valuation and Earnings

Biolase has a net margin of -58.13% compared to Milestone Scientific's net margin of -13.16%. Milestone Scientific's return on equity of -61.33% beat Biolase's return on equity of -21668.17%.

Milestone Scientific has a consensus price target of $2.13, signalling upside risk potential of 137.43%. On the other hand Biolase has an analysts' consensus of $1.2000 which suggests that it could grow by 19130.77%. Given that Biolase has higher upside potential than Milestone Scientific, analysts believe Biolase is more attractive than Milestone Scientific.

Milestone Scientific has a beta of 0.934, which suggesting that the stock is 6.585% less volatile than S&P 500. In comparison Biolase has a beta of 0.016, suggesting its less volatile than the S&P 500 by 98.394%.

Milestone Scientific has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Biolase offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Milestone Scientific pays -- of its earnings as a dividend. Biolase pays out -- of its earnings as a dividend.

Milestone Scientific quarterly revenues are $2.5M, which are smaller than Biolase quarterly revenues of $10.9M. Milestone Scientific's net income of -$1.5M is lower than Biolase's net income of -$1.4M. Notably, Milestone Scientific's price-to-earnings ratio is -- while Biolase's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Milestone Scientific is 8.25x versus 0.01x for Biolase. Usually stocks with elevated PS ratios are considered overvalued.

Envista Holdings has a net margin of -58.13% compared to Milestone Scientific's net margin of 2.92%. Milestone Scientific's return on equity of -61.33% beat Envista Holdings's return on equity of -34.78%.

Milestone Scientific has a consensus price target of $2.13, signalling upside risk potential of 137.43%. On the other hand Envista Holdings has an analysts' consensus of $19.13 which suggests that it could grow by 4.68%. Given that Milestone Scientific has higher upside potential than Envista Holdings, analysts believe Milestone Scientific is more attractive than Envista Holdings.

Milestone Scientific has a beta of 0.934, which suggesting that the stock is 6.585% less volatile than S&P 500. In comparison Envista Holdings has a beta of 0.975, suggesting its less volatile than the S&P 500 by 2.472%.

Milestone Scientific has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Envista Holdings offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Milestone Scientific pays -- of its earnings as a dividend. Envista Holdings pays out -- of its earnings as a dividend.

Milestone Scientific quarterly revenues are $2.5M, which are smaller than Envista Holdings quarterly revenues of $616.9M. Milestone Scientific's net income of -$1.5M is lower than Envista Holdings's net income of $18M. Notably, Milestone Scientific's price-to-earnings ratio is -- while Envista Holdings's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Milestone Scientific is 8.25x versus 1.26x for Envista Holdings. Usually stocks with elevated PS ratios are considered overvalued.

Solventum has a net margin of -58.13% compared to Milestone Scientific's net margin of 6.62%. Milestone Scientific's return on equity of -61.33% beat Solventum's return on equity of 11.75%.

Milestone Scientific has a consensus price target of $2.13, signalling upside risk potential of 137.43%. On the other hand Solventum has an analysts' consensus of $80.14 which suggests that it could grow by 8.14%. Given that Milestone Scientific has higher upside potential than Solventum, analysts believe Milestone Scientific is more attractive than Solventum.

Milestone Scientific has a beta of 0.934, which suggesting that the stock is 6.585% less volatile than S&P 500. In comparison Solventum has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Milestone Scientific has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Solventum offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Milestone Scientific pays -- of its earnings as a dividend. Solventum pays out -- of its earnings as a dividend.

Milestone Scientific quarterly revenues are $2.5M, which are smaller than Solventum quarterly revenues of $2.1B. Milestone Scientific's net income of -$1.5M is lower than Solventum's net income of $137M. Notably, Milestone Scientific's price-to-earnings ratio is -- while Solventum's PE ratio is 34.31x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Milestone Scientific is 8.25x versus 1.55x for Solventum. Usually stocks with elevated PS ratios are considered overvalued.

Dentsply Sirona has a net margin of -58.13% compared to Milestone Scientific's net margin of 2.28%. Milestone Scientific's return on equity of -61.33% beat Dentsply Sirona's return on equity of -35.57%.

Milestone Scientific has a consensus price target of $2.13, signalling upside risk potential of 137.43%. On the other hand Dentsply Sirona has an analysts' consensus of $18.14 which suggests that it could grow by 9.89%. Given that Milestone Scientific has higher upside potential than Dentsply Sirona, analysts believe Milestone Scientific is more attractive than Dentsply Sirona.

Milestone Scientific has a beta of 0.934, which suggesting that the stock is 6.585% less volatile than S&P 500. In comparison Dentsply Sirona has a beta of 0.924, suggesting its less volatile than the S&P 500 by 7.642%.

Milestone Scientific has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Dentsply Sirona offers a yield of 3.88% to investors and pays a quarterly dividend of $0.16 per share. Milestone Scientific pays -- of its earnings as a dividend. Dentsply Sirona pays out -13.85% of its earnings as a dividend.

Milestone Scientific quarterly revenues are $2.5M, which are smaller than Dentsply Sirona quarterly revenues of $879M. Milestone Scientific's net income of -$1.5M is lower than Dentsply Sirona's net income of $20M. Notably, Milestone Scientific's price-to-earnings ratio is -- while Dentsply Sirona's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Milestone Scientific is 8.25x versus 0.89x for Dentsply Sirona. Usually stocks with elevated PS ratios are considered overvalued.